French pharmaceutical company Sanofi is in talks with Swiss drugmaker Actelion, but a deal is not imminent, sources confirmed to CNBC on Wednesday.
U.S. shares of Actelion and Sanofi were down 9 percent and 2.5 percent, respectively, on Wednesday.
It’s unclear what price Sanofi might pay or what structure is envisioned, but the deal could value Actelion as much as $30 billion, according to The Wall Street Journal, which first reported on the talks and cited people familiar with the matter.
On Tuesday, Johnson & Johnson ended its discussions with Actelion regarding a possible transaction. Actelion told J&J it was confident it could attract a higher offer than the 250 Swiss francs per share the U.S. company had offered, Reuters reported.
In August, Sanofi, eager for deals to broaden its drug lineup, was trumped by Pfizer’s $14 billion bid for U.S. cancer drug company Medivation.
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.